Arch Biopartners Inc.

ACHFF

CA03938C1041

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 17:37:23 04/03/2026 GMT			5-day change	1st Jan Change
0.5800 ^USD	+0.87%		-5.23%	-34.34%

03-03	Arch Biopartners Inc. Reports Earnings Results for the First Quarter Ended December 31, 2025	CI
02-09	Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease	CI

Arch Biopartners Inc. Auditor Raises 'Going Concern' Doubt

Published on 01/28/2026

S&P Capital IQ

ARCH BIOPARTNERS INC.

+0.87%

Arch Biopartners Inc. filed its Annual on Jan 29, 2026 for the period ending Sep 30, 2025. In this report its auditor, Baker Tilly, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Latest news about Arch Biopartners Inc.

03-03	Arch Biopartners Inc. Reports Earnings Results for the First Quarter Ended December 31, 2025	CI
02-09	Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease	CI
01-29	Arch Biopartners Inc. Reports Earnings Results for the Full Year Ended September 30, 2025	CI
01-28	Arch Biopartners Inc. Auditor Raises 'Going Concern' Doubt	CI
01-16	Arch Biopartners Appoints Patrick Vink as Chairman	MT
01-16	Arch Biopartners Inc. Announces Appointment of Patrick Vink as Chairman of the Board and Retirement of Claude Allary from the Board of Directors	CI
12-16	Arch Biopartners Says Toronto's St Michael's Hospital Cleared to Participate in Phase II Trial Related To Kidney Injury	MT
12-16	Arch Biopartners Inc. Announces Ethics Approval for St. Michael's Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide	CI
11-19	Arch Biopartners closes non-brokered private placement	RE
11-18	Arch Biopartners Inc. announced that it has received CAD 0.6 million in funding	CI
11-10	Arch Biopartners to Launch $500,000 Non-Brokered Private Placement Offering	MT
11-10	Arch Biopartners Inc. announced that it expects to receive CAD 0.5 million in funding	CI
11-05	Arch Biopartners Expands Phase II Cardiac Surgery-Associated AKI Trial to Include Royal Columbian Hospital in British Columbia	MT
11-05	Arch Biopartners Expands Phase II Cardiac Surgery-Associated AKI Trial to Include Royal Columbian Hospital in British Columbia	CI
20/10/25	Arch Biopartners Inc.(TSXV:ARCH) dropped from S&P/TSX Venture Composite Index	CI

Chart Arch Biopartners Inc.

Duration

Period

ACHFF: Dynamic Chart

Company Profile

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Companyâ€™s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

Employees

Sector

Pharmaceuticals

More about the company